Search Torrents
|
Browse Torrents
|
48 Hour Uploads
|
TV shows
|
Music
|
Top 100
Audio
Video
Applications
Games
Porn
Other
All
Music
Audio books
Sound clips
FLAC
Other
Movies
Movies DVDR
Music videos
Movie clips
TV shows
Handheld
HD - Movies
HD - TV shows
3D
Other
Windows
Mac
UNIX
Handheld
IOS (iPad/iPhone)
Android
Other OS
PC
Mac
PSx
XBOX360
Wii
Handheld
IOS (iPad/iPhone)
Android
Other
Movies
Movies DVDR
Pictures
Games
HD - Movies
Movie clips
Other
E-books
Comics
Pictures
Covers
Physibles
Other
Details for:
Hoffbrand A. Hoffbrand's Essential Haematology 9ed 2024
hoffbrand hoffbrand s essential haematology 9ed 2024
Type:
E-books
Files:
2
Size:
38.3 MB
Uploaded On:
Oct. 30, 2024, 2:46 p.m.
Added By:
andryold1
Seeders:
14
Leechers:
3
Info Hash:
276A3D120548F8ECB73803C96B8EDFE70CF93A7A
Get This Torrent
Textbook in PDF format Advances in the understanding the pathogenesis of blood diseases and improvements in their treatment have continued apace in the 5 years since the eighth edition of Hoffbrand’s Essential Haematology was published. Gene mutations are increasingly used to define and classify inherited and acquired haematological diseases, as a guide to therapy and to predict prognosis. Mutations underlying many rarer blood diseases have been identified, allowing appropriate panels of DNA probes to be established, facilitating the diagnosis of future cases. Many more drugs directed against specific sites in the cell signalling pathways have been approved. The past five years have also seen substantial advances in immunological treatment for malignant haematological diseases. Mono-and bi-specific antibodies are increasingly incorporated into frontline therapy as well into treatment of relapsed disease. Chimeric antigen receptor (CAR)-T cells are challenging stem cell transplantation for potential cure for relapsed B-cell lymphoid neoplasms. New drugs have also been introduced for treatment of benign (now termed in the United States ‘classical’) haematological diseases. These include mitapivat for pyruvate kinase deficiency, sutimlimab for cold agglutinin disease, luspatercept for anaemia in thalassaemia and myelodysplasia and pegcetacoplan for paroxysmal nocturnal haemoglobinuria. Drugs inhibiting prolyl hydroxylase in the hypoxia-inducible factor pathway are being developed to treat anaemia. They are already in illegal use for ‘doping’ of athletes to enhance their performance
Get This Torrent
Readme.txt
645 bytes
Hoffbrand A. Hoffbrand's Essential Haematology 9ed 2024.pdf
38.3 MB
